IP Library Granted Patent US 8,829,030
Granted Patent B2
US 8,829,030 · App. 13/690,290 · Granted Sep 9, 2014

Compounds and methods for the treatment or prevention of

Inventors: Laval Chan Chun Kong (Kirkland, CA); Sanjoy Kumar Das (Pierrefonds, CA); Nghe Nguyen-Ba (LaPrairie, CA); Liliane Halab (Outremont, CA); Bettina Hamelin (Sillery, CA); Oswy Z. Pereira (Kirkland, CA); Carl Poisson (Montreal, CA); Melanie Proulx (Knowlton, CA); Thunkunta Jagadeeswar Reddy (Peirrefonds, CA); Ming Qiang Zhang (Kirkland, CA)
Assignee: Vertex Pharmaceuticals (Canada) Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,829,030
App. No.
13/690,290
Granted
Sep 9, 2014
Kind
B2
Abstract

Compounds represented by formula: Wherein X, Y and Z are as defined herein, pharmaceutically acceptable salts thereof, and related compounds, are suitable for use in treating or preventing a Flaviviridae viral infection in a host.

Claims (61)

1. A compound of formula:

or pharmaceutically acceptable salts thereof;

wherein;

Z is piperidinyl or N—C 1-6 alkyl-piperidinyl;

Y is 6-10 membered aryl;

X is 3-10 membered cycloalkyl;

m is an integer from 0-1;

provided that when Y is unsubstituted phenyl then X is other than 4-methylcyclohexane.

2. A compound according to claim 1 , wherein Z is piperidinyl or N—(C 1-6 alkyl)-piperidinyl, N—(C 1-6 alkyl)-piperidinylmethyl, or piperidinylmethyl, which in each case is unsubstituted or substituted by one or more substituent chosen from halogen, nitro, nitroso, SO 3 Rf, SO 2 Rf, PO 3 RcRd, CONRgRh, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-12 aralkyl, C 6-12 aryl, C 1-6 alkyloxy, C 2-6 alkenyloxy, C 2-6 alkynyloxy, C 6-12 aryloxy, C(O)C 1-6 alkyl, C(O)C 2-6 alkenyl, C(O)C 2-6 alkynyl, C(O)C 6-12 aryl, C(O)C 6-12 aralkyl, C(O)NHRf, C 3-10 heterocycle, hydroxyl, NRgRh, C(O)ORf, cyano, azido, amidino or guanido;

wherein Rf, Rc, Rd, Rg and Rh in each case is H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 heterocycle, C 3-10 heteroaralkyl or C 6-10 aralkyl;

or Rc and Rd are taken together with the oxygens to form a 5 to 10 membered heterocycle;

or Rg and Rh are taken together with the nitrogen to form a 3 to 10 membered heterocycle.

3. A compound according to claim 1 , wherein Z is piperidinyl unsubstituted or substituted by one or more substituent chosen from halogen, SO 2 Rf, CONRgRh, C 1-6 alkyl, C 6-12 aralkyl, C 6-12 aryl, C 1-6 alkyloxy, C(O)C 1-6 alkyl, C(O)NHRf, C 3-10 heterocycle, hydroxyl, NRgRh, C(O)Orf or cyano;

wherein Rf, Rg and Rh in each case is H or C 1-6 alkyl.

4. A compound according to claim 1 , wherein Z is N—(C 1-6 alkyl)-piperidinyl unsubstituted or substituted by one or more substituent chosen from halogen, SO 2 Rf, CONRgRh, C 1-6 alkyl, C 6-12 aralkyl, C 6-12 aryl, C 1-6 alkyloxy, C(O)C 1-6 alkyl, C(O)NHRf, C 3-10 heterocycle, hydroxyl, NRgRh, C(O)Orf or cyano;

wherein Rf, Rg and Rh in each case is H or C 1-6 alkyl.

5. A compound according to claim 1 , wherein X is 6-membered cycloalkyl.

6. A compound according to claim 1 , wherein X is cyclohexyl unsubstituted or substituted by one or more substituent chosen from halogen, nitro, nitroso, SO 3 Rf, SO 2 Rf, PO 3 RcRd, CONRgRh, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-12 aralkyl, C 6-12 aryl, C 1-6 alkyloxy, C 2-6 alkenyloxy, C 2-6 alkynyloxy, C 6-12 aryloxy, C(O)C 1-6 alkyl, C(O)C 2-6 alkenyl, C(O)C 2-6 alkynyl, C(O)C 6-12 aryl, C(O)C 6-12 aralkyl, C(O)NHRf, C 3-10 heterocycle, hydroxyl, NRgRh, C(O)ORf, cyano, azido, amidino or guanido;

wherein Rf, Rc, Rd, Rg and Rh in each case is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 heterocycle, C3-10 heteroaralkyl or C6-10 aralkyl;

or Rc and Rd are taken together with the oxygens to form a 5 to 10 membered heterocycle;

or Rg and Rh are taken together with the nitrogen to form a 3 to 10 membered heterocycle.

7. A compound according to claim 1 , wherein X is cyclohexyl substituted by one or more substituent chosen from C 1-6 alkyl, halogen, C 2-6 alkenyl, C 2-6 alkynyl or C 1-6 alkyloxy.

8. A compound according to claim 1 , wherein X is 4-methyl-cyclohexyl or 2-hydroxy-4-methyl-cyclohexyl.

9. A compound according to claim 1 , wherein Y is phenyl unsubstituted or substituted by one or more substituent chosen from halogen, nitro, nitroso, SO 3 Rf, SO 2 Rf, PO 3 RcRd, CONRgRh, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-12 aralkyl, C 6-12 aryl, C 1-6 alkyloxy, C 2-6 alkenyloxy, C 2-6 alkynyloxy, C 6-12 aryloxy, C(O)C 1-6 alkyl, C(O)C 2-6 alkenyl, C(O)C 2-6 alkynyl, C(O)C 6-12 aryl, C(O)C 6-12 aralkyl, C(O)NHRf, C 3-10 heterocycle, hydroxyl, NRgRh, C(O)ORf, cyano, azido, amidino or guanido;

wherein Rf, Rc, Rd, Rg and Rh in each case is H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 heterocycle, C 3-10 heteroaralkyl or C 6-10 aralkyl;

or Rc and Rd are taken together with the oxygens to form a 5 to 10 membered heterocycle;

or Rg and Rh are taken together with the nitrogen to form a 3 to 10 membered heterocycle.

10. A compound according to claim 1 , wherein Y is phenyl substituted by one or more substituent chosen from halogen, nitro, SO 2 Rf, C 1-6 alkyl, C 1-6 alkyloxy, C(O)C 1-6 alkyl, C(O)Orf, cyano or azido.

11. A compound according to claim 1 , wherein Y is phenyl.

12. A compound chosen from:

3-{[(2-carboxy-5-phenyl-thiophen-3-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-methyl}-piperidinium; trifluoro-acetate;

2-{[(2-carboxy-5-phenyl-thiophen-3-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-methyl}-piperidinium; trifluoro-acetate;

4-[(2-carboxy-5-phenyl-thiophen-3-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-1-methyl-piperidinium chloride;

4-[[2-carboxy-5-(4-fluoro-phenyl)-thiophen-3-yl]-(4-methyl-cyclohexanecarbonyl)-amino]-1-methyl-piperidinium chloride;

3-[(4-methyl-cyclohexanecarbonyl)-(1-methyl-piperidin-4-ylmethyl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

3-{[(2-carboxy-5-phenyl-thiophen-3-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-methyl}-1-methyl-piperidinium chloride;

4-{[(2-carboxy-5-phenyl-thiophen-3-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-methyl}-1-methyl-piperidinium chloride;

3-[(1-ethyl-piperidin-4-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

3-[(1-isopropyl-piperidin-4-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

3-[(4-methyl-cyclohexanecarbonyl)-piperidin-4-yl-amino]-5-phenyl-thiophene-2-carboxylic acid;

4-[(2-carboxytolyl-thiophen-3-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-1-methyl-piperidinium chloride;

3-[(1-acetyl-piperidin-4-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

3-[(1-benzyl-piperidin-4-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

4-[[2-carboxy-5-(3-fluoro-phenyl)-thiophen-3-yl]-(4-methyl-cyclohexanecarbonyl)-amino]-1-methyl-piperidinium; chloride;

4-[[2-carboxy-5-(4-methoxy-phenyl)-thiophen-3-yl]-(4-methyl-cyclohexanecarbonyl)-amino]-1-methyl-piperidinium; chloride;

4-[[2-carboxy-5-(4-nitro-phenyl)-thiophen-3-yl]-(4-methyl-cyclohexanecarbonyl)-amino]-1-methyl-piperidinium; chloride;

4[[2-carboxy-5-(4-chloro-phenyl)-thiophen-3-yl]-(4-methyl-cyclohexanecarbonyl)-amino]-1-methyl-piperidinium chloride;

4-[[2-carboxy-5-(4-cyano-phenyl)-thiophen-3-yl]-(4-methyl-cyclohexanecarbonyl)-amino]-1-methyl-piperidinium chloride;

3-[(1-formyl-piperidin-4-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

3-[(4-methyl-cyclohexanecarbonyl)-(1-methyl-1-oxy-piperidin-4-yl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

3-[(4-methyl-cyclohexanecarbonyl)-(1-methyl-1-oxy-piperidin-4-yl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

3-[(1-methanesulfonyl-piperidin-4-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

3-[(1-methylcarbamoyl-piperidin-4-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

3-[(1-methylcarbamoyl-piperidin-4-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

3-[(4-methyl-cyclohexanecarbonyl)-(1-methyl-2-oxo-piperidin-4-yl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

3-[(1-cyano-piperidin-4-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

3-[(1-carbamoyl-piperidin-4-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

3-[(1-aminooxalyl-piperidin-4-yl)-(4-methyl-cyclohexanecarbonyl)-amino]-5-phenyl-thiophene-2-carboxylic acid;

or pharmaceutically acceptable salts thereof.

13. A compound as defined in claim 12 ; wherein said pharmaceutically acceptable salt is sodium salt.

14. A pharmaceutical composition comprising at least one compound as defined in claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2013
From: SHIRE BIOCHEM INC.
To: VIROCHEM PHARMA INC.
Reel/Frame 031535/0271 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2013
From: CHAN CHUN KONG, LAVAL; DAS, SANJOY KUMAR; NGUYEN-BA, NGHE; HALAB, LILIANE; HAMELIN, BETTINA; PEREIRA, OSWY Z.; POISSON, CARL; PROULX, MELANIE; REDDY, THUMKUNTA JAGADEESWAR; ZHANG, MING-QIANG
To: SHIRE BIOCHEM INC.
Reel/Frame 031535/0750 →
MERGER Recorded Nov 4, 2013
From: VIROCHEM PHARMA INC.
To: VERTEX PHARMACEUTICALS (CANADA) INCORPORATED
Reel/Frame 031560/0858 →
Continuity (4)
Continuation 12068237 · Feb 4, 2008
Continuation 10730272 · Dec 9, 2003
Provisional Application 60431964 · Dec 10, 2002
Related Publication 20130096106A1 · Apr 18, 2013